AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 DEC 4 - (NewsRx.com & NewsRx.net) -- Imaging Diagnostic Systems, Inc., (IMDS) announced the signing of a collaborative agreement with the Rumbaugh-Goodwin Institute (RGI) for Cancer Research, Inc., for the development of optical imaging products for the laboratory market.
Linda Grable, CEO, stated, "With this agreement, IDSI is addressing a new market, targeting pharmaceutical developers and researchers who monitor cancer growth. It is exciting and beneficial to be adding a new product line to complement our CTLM breast imaging product. This work draws on the 9 years of R&D at Imaging Diagnostics in the optical imaging field, particularly drawing on the fluorescence work we have done at the University of Virginia and the cooperative work with Schering, AG."
Robert Wake, vice president of engineering, stated, "An extension of IDSI's optical computed tomography [CT] and fluorescent imaging technologies is the development of a new product line: Laser Imaging for Lab Animals (LILA). The first model of the LILA product line is a miniature optical CT scanner for imaging green fluorescent protein, derived from the DNA of jellyfish. This product is addressing a new market, targeting pharmaceutical developers and researchers who use optical imaging in their clinical research. The scanner is the first of a series of optical imaging products for the research laboratory."
Dr. Alex Aller, director of RGI, said, "The LILA will provide a powerful tool for ...
Source: HighBeam Research, Imaging company inks agreement with the Rumbaugh-Goodwin Institute.